ReviewMediators of inflammation2010
Modulation of Toll-like receptor activity by leukocyte Ig-like receptors and their effects during bacterial infection.
Review in Mediators of inflammation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Advances in molecular innate immune regulation in the development and therapeutic strategies of allergic rhinitis vaccines.Frontiers in immunology · 2026Review
- Article
- Modulated Autophagy by MicroRNAs in Osteoarthritis Chondrocytes.BioMed research international · 2019Review
- TLR8 regulation of LILRA3 in monocytes is abrogated in human immunodeficiency virus infection and correlates to CD4 counts and virus loads.Retrovirology · 2016Article
- Expression of the innate immune receptor LILRB5 on monocytes is associated with mycobacteria exposure.Scientific reports · 2016Article
- Leukocyte Ig-Like Receptors - A Model for MHC Class I Disease Associations.Frontiers in immunology · 2016Review
- Fc receptors in antibody-dependent enhancement of viral infections.Immunological reviews · 2015Review
- Genome-wide whole blood microRNAome and transcriptome analyses reveal miRNA-mRNA regulated host response to foodborne pathogen Salmonella infection in swine.Scientific reports · 2015Article
- Copy number and nucleotide variation of the LILR family of myelomonocytic cell activating and inhibitory receptors.Immunogenetics · 2014Article
- Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance.Molecular medicine reports · 2012Article
- The response of human dendritic cells to co-ligation of pattern-recognition receptors.Immunologic research · 2012Review
- Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.PloS one · 2012Article
- Characterisation of bovine leukocyte Ig-like receptors.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptors (TLRs) are a potent trigger for inflammatory immune responses. Without tight regulation their activation could lead to pathology, so it is imperative to extend our understanding of the regulatory mechanisms that govern TLR expression and function. One family of immunoregulatory proteins which can provide a balancing effect on TLR activity are the Leukocyte Ig-like receptors (LILRs), which act as innate immune receptors for self-proteins. Here we describe the LILR family, their inhibitory effect on TLR activity in cells of the monocytic lineage, their signalling pathway, and their antimicrobial effects during bacterial infection. Agents have already been identified which enhances or inhibits LILR activity raising the future possibility that modulation of LILR function could be used as a means to modulate TLR activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.